Trial Profile
A Double-blind, Randomized, Placebo-controlled Study to Determine the Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia in Midlife Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 14 Mar 2022 Results of efficacy of the dual orexin receptor antagonist suvorexant for chronic insomnia related to nighttime VMS,published in the Sleep
- 03 Oct 2020 Primary endpoint has been met. (Change in ISI score)
- 03 Oct 2020 Results presented at the North American Menopause Society 2020 Annual Meeting